Creo Medical (CREO) AI Stock Analysis

• Market Cap: £45.89M
• Dividend Yield: N/A
• Average Volume (3M): 975.48K
• Price to Earnings (P/E): 0.8
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 278
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.00
• Shares Outstanding: 412,473,330
• 10 Day Avg. Volume: 668,834
• 30 Day Avg. Volume: 975,484
• PEG Ratio: -0.17
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 17.63
• P/FCF Ratio: -3.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): £9.38M

• Rating: 48 Neutral
• Price Target: 14.00 p ▲(37.93% Upside)
• Action: Downgraded Date: 01/29/26
• Date: Action: Downgraded 01/29/26

The score is held back primarily by poor financial performance (sharp revenue decline, large losses, and continued cash burn). Technicals are a partial offset with strong trend and positive MACD, but very overbought RSI increases near-term risk. Valuation impact is neutral since P/E and dividend yield were not provided.

Positive Factors

Recurring consumables revenue

Creo's business model includes recurring consumable sales tied to each procedure. This creates a durable, predictable revenue stream once clinical adoption is established, improving lifetime customer value and smoothing unit-sales volatility over the medium term.

Negative Factors

Severe revenue decline

A collapse in revenue indicates material loss of commercial traction or discontinued operations, shrinking scale and limiting the firm's ability to achieve operating leverage. This structural shrinkage raises the likelihood of further capital raises and constrains long‑term market positioning.

Creo Medical Business Overview & Revenue Model

Company Description

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal device...

Read more

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal device...

How the Company Makes Money

Creo Medical generates revenue primarily through the sale of its medical devices and related consumables. The company earns money by selling its CROMA system and the associated single-use devices required for its operation during surgical procedur...

Read more

Creo Medical generates revenue primarily through the sale of its medical devices and related consumables. The company earns money by selling its CROMA system and the associated single-use devices required for its operation during surgical procedur...

Creo Medical Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.20M	4.00M	30.80M	27.17M	25.16M	9.43M
Gross Profit	1.00M	1.90M	15.30M	10.01M	9.02M	2.44M
EBITDA	-9.50M	-26.10M	-20.70M	-27.62M	-27.54M	-21.77M
Net Income	16.90M	-28.70M	-21.70M	-26.94M	-24.59M	-20.32M
Balance Sheet
Total Assets	68.80M	65.00M	76.60M	75.34M	100.61M	92.46M
Cash, Cash Equivalents and Short-Term Investments	20.50M	8.70M	18.50M	13.10M	43.53M	45.09M
Total Debt	4.20M	4.40M	8.30M	11.70M	10.56M	12.36M
Total Liabilities	7.90M	22.60M	16.80M	25.93M	27.29M	29.66M
Stockholders Equity	60.90M	42.40M	59.80M	49.40M	73.32M	62.81M
Cash Flow
Free Cash Flow	15.30M	-22.60M	-22.80M	-28.26M	-32.10M	-16.66M
Operating Cash Flow	15.30M	-22.20M	-21.60M	-24.99M	-25.98M	-16.09M
Investing Cash Flow	-3.30M	15.30M	-18.30M	-6.03M	-7.87M	-21.16M
Financing Cash Flow	-600.00K	16.20M	29.80M	400.00K	31.99M	1.33M

Creo Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Negative. The current price of 10.15 is below the 20-day moving average (MA) of 12.32, below the 50-day MA of 14.31, and below the 200-day MA of 12.43, indicating a bearish trend. The MACD of -0.93 indicates Positive momentum. The RSI at 32.09 is Neutral, neither overbought nor oversold. The STOCH value of 31.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CREO.

Creo Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	74 Outperform	£182.14M	12.60	23.64%	3.48%	10.80%	1.75%
SN	70 Outperform	£10.46B	22.64	11.79%	2.35%	2.51%	56.56%
AMS	56 Neutral	£439.30M	47.21	3.87%	1.25%	68.03%	-18.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CREO	48 Neutral	£45.89M	0.83	32.72%	―	―	―
SUN	43 Neutral	£4.20M	77.73	-16.78%	―	-4.98%	-114.29%

Creo Medical Corporate Events